Project Details
Description
Phase I/II Study of Nivolumab in Combination with Ruxolitinib in Relapsed or Refractory Hodgkin's Lymphoma Hodgkin???s Lymphoma
Status | Active |
---|---|
Effective start/end date | 8/16/18 → 8/15/28 |
Funding
- BRISTOL-MYERS SQUIBB COMPANY
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.